|Application ||WB, IHC-P, IF, FC, E|
|Calculated MW||57305 Da|
|Antigen Region||217-246 aa|
|Other Names||Alkaline phosphatase, tissue-nonspecific isozyme, AP-TNAP, TNSALP, Alkaline phosphatase liver/bone/kidney isozyme, ALPL|
|Target/Specificity||This ALPL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 217-246 amino acids from the Central region of human ALPL.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||ALPL Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||This isozyme may play a role in skeletal mineralization.|
|Cellular Location||Cell membrane; Lipid-anchor, GPI-anchor|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
There are at least four distinct but related alkaline phosphatases: intestinal, placental, placental-like, and liver/bone/kidney (tissue non-specific). The genes for the first three are located together on chromosome 2 while the tissue non-specific form is located on chromosome 1. This protein is a membrane bound glycosylated enzyme that is not expressed in any particular tissue and is, therefore, referred to as the tissue-nonspecific form of the enzyme. The exact physiological function of the alkaline phosphatases is not known. A proposed function of this form of the enzyme is matrix mineralization, however, mice that lack a functional form of this enzyme show normal skeletal development. This enzyme has been linked directly to a disorder known as hypophosphatasia, a disorder that is characterized by hypercalcemia and includes skeletal defects. The character of this disorder can vary, however, depending on the specific mutation since this determines age of onset and severity of symptoms.
Panuccio,V., Am. J. Kidney Dis. 50 (6), 1001-1008 (2007)
Brun-Heath,I., Eur J Med Genet 50 (5), 367-378 (2007)
So,P.P., J. Rheumatol. 34 (6), 1313-1322 (2007)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.